Developer of capillary agglutination technology for point of care testing has secured a further £500k from two investment funds and appoints new chairman and CSO
Platform Diagnostics, developer of capillary agglutination technology for point of care testing, has secured a further £500k from the Rising Stars growth fund and the North West Equity Fund. The company also announced the appointment of David Evans as chairman and Gerry Allen as chief scientific officer.
With a successful background of raising venture capital, steering companies through strategic changes and overseeing the introduction of new technologies, David Evans is said to be ideally suited to guide Platform Diagnostics through the next stage of its development.
A former finance director of Shield Diagnostics, he saw the company through flotation, later becoming managing director to head the merger with Axis Biochemicals to form Axis-Shield.
Under his leadership as non executive chairman of British Biocell, the company's outstanding growth and increased profitability enabled it to float on the AIM in 2004. David Evans's experience of growing a number of early start up companies by introducing technologies attractive to investors and structuring collaborative deals will be directly applicable to his new role.
Gerry Allen brings extensive experience of leading immunoassay research and development teams in the diagnostics field, successfully launching many new tests onto the market.
He has experience of QC, QA and regulatory affairs issues and taken responsibility for streamlining manufacturing operations.
Allen has worked for several organisations, both in the UK and USA, including Amersham International, R and D Systems, and Metra Biosystems.
